Accuray presents promising data

Posted on Jul 11, 2011

Leading radiosurgery systems maker Accuray Incorporated has presented encouraging new clinical data highlighting the benefits of its CyberKnife radiosurgery system and its recently acquired TomoTherapy radiation therapy system in treating a vast continuum of lung cancer patients.

The data was presented at the World Conference on Lung Cancer (“WCLC”), which took place in Amsterdam, between July 3 and 7, 2011. WCLC, hosted by the International Association for the Study of Lung Cancer (“IASLC”), is the leading international forum for lung cancer and thoracic oncology research and practice.

The CyberKnife system delivers ablative doses of radiation to lung tumors with the highest levels of accuracy. Moreover, the TomoTherapy system delivers high quality intensity modulated radiation therapy (“IMRT”) for larger, complex tumors as well as destructive radiation doses for smaller peripheral lung tumors.

Accuray presented data from two clinical studies, conducted in The Netherlands, at the WCLC that showcase the ability of the CyberKnife and TomoTherapy systems to deliver stereotactic body radiotherapy (“SBRT”), a non-invasive radiotherapy procedure, for primary lung cancer and lung metastases.

The first study, in which 89 patients were treated with the TomoTherapy system, revealed high rates of local tumor control with low toxicity in a heterogeneous group of patients. Many of these patients had previously undergone surgery or conventional radiotherapy. Two-year progression free survival in this study was 95%.

The second study evaluated the effectiveness of the CyberKnife system in treating 56 patients with metastatic lung tumors with many having multiple tumors. The researchers leveraged CyberKnife’s unique tumor tracking and robotic correcting capabilities to quickly deliver high doses of radiation therapy to attain high rates of tumor control with low side effects irrespective of tumor location. The results suggest the effectiveness of these therapies in extending treatments options for lung cancer patients.


This page was printed from OSL Web site at http://www.osl.uk.com